- In March 2021, Pfizer Inc. received FDA approval for a supplemental New Drug Application (sNDA) for LORBRENA (lorlatinib), expanding its indication to include first-line treatment for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
- On November 2023, the U.S. Food and Drug Administration (FDA) approved Augtyro™ (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)
